To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 40 Years - 75 Years
- Sexes
- All
Research at a glance
Top areas of exploration
- Parkinson Disease , 43 publications
- Supranuclear Palsy, Progressive , 18 publications
- Multiple System Atrophy , 14 publications
- Parkinsonian Disorders , 13 publications
Research activity
Focus
Dr. McFarland is a member of the Norman Fixel Institute for Neurological Diseases and the Center for Translational Research in Neurodegenerative Disease (CTRND), which aims to bring the bench research closer to the bedside. His research focuses on understanding the pathological mechanisms of Parkinson disease and related disorders, and on identifying novel biomarkers for early detection and tracking of disease and therapeutic development. A primary goal of his research is to identify and to develop potential novel therapeutics for Parkinson disease and related disorders. His research extends also to the clinic where he is actively involved in multiple clinical trials for atypical Parkinson disorders and Huntington disease.
Active clinical trials
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label…
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 40 Years - 80 Years
- Sexes
- All
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in…
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 30 Years - 80 Years
- Sexes
- All
My publications
Filter publications
97 publications
2015
Unexpected dual task benefits on cycling in Parkinson disease and healthy adults: a neuro-behavioral model.
PloS one
•2015
Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice.
Molecular neurodegeneration
•2015
Weight loss and impact on quality of life in Parkinson's disease.
PloS one
•2014
An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.
PloS one
•2014
Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss.
PloS one
•